Osteonecrosis associated with short-term oral administration of bisphosphonate.
Orally administered bisphosphonates are generally considered a first-line medication for treatment of osteoporosis. As a side effect of bisphosphonates, osteonecrosis of the jaws (ONJ) has been reported worldwide. Most reports of osteonecrosis are attributed to the use of bisphosphonates administered intravenously for the treatment of bone disorders such as multiple myeloma. However, osteonecrosis has also been diagnosed in patients receiving oral bisphosphonates. The management of a patient with spontaneous removable partial denture prosthesis-related ONJ associated with short-term oral administration of bisphosphonate is described.
Takagi
Yuki
Y
Division of Oral and Dental Surgery, Department of Advanced Medicine, National Center for Geriatrics and Gerontology, Obu, Aichi 474-8511, Japan.
Sumi
Yasunori
Y
Harada
Atsushi
A
D000284:Administration, Oral; D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003832:Denture, Partial, Removable / Q000009:adverse effects*; D012968:Etidronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008334:Mandible; D008336:Mandibular Diseases / Q000139:chemically induced* / Q000209:etiology; D019226:Oral Ulcer / Q000150:complications / Q000209:etiology*; D010020:Osteonecrosis / Q000139:chemically induced* / Q000209:etiology; D000068296:Risedronic Acid; D014945:Wound Healing
D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid